Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
Recruiting · NCT04966481 · Registry updated 2026-09-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | HPV-unrelated Head and Neck Squamous Cell Carcinoma | Recruiting | Phase 3 | 2026-09-22 | NCT04966481 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pfizer | 431 |
| The Joseph Sanchez Foundation | 3 |
| Washington University School of Medicine | 475 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Saint Luke's Hospital | Kansas City | United States | 9 |
| Sanford Medical Center | Sioux Falls | United States | 1 |
| Sanford Roger Maris Cancer Center | Fargo | United States | 201 |
| Sanford Worthington Medical Center | Worthington | United States | 4 |
| Washington University School of Medicine | St Louis | United States | 895 |